北米のタキサン市場 – 業界動向と2029年までの予測

市場分析と洞察

北米のタキサン市場は、2022年から2029年の予測期間に市場が成長すると予想されています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に7.7%のCAGRで成長すると分析しています。タキサン薬物治療の技術的進歩とコンピューター支援診断の応用の増加は、予測期間におけるタキサン市場の成長を促進する他の要因です。

しかし、この薬剤のコストの高さと、血栓、白血球減少症、アレルギー、下痢、体重減少などの副作用が市場の成長を抑制します。主要な市場プレーヤーによるパートナーシップや買収などの戦略的提携の採用は、タキサン市場の成長の機会となります。

タキサン市場の定義

タキサンまたはタキソイドは、有糸分裂阻害剤としての独自の作用機序を持つ、密接に関連した抗腫瘍剤のグループであり、卵巣がん、乳がん、肺がん、食道がん、前立腺がん、膀胱がん、頭頸部がんの治療に広く使用されています。臨床で使用されているタキサンは、パクリタキセル (タキソール: 1992)、ドセタキセル (タキソテール: 1996)、カバジタキセル (ジェブタナ: 2010) の 3 つです。タキサンは、微小管の機能を妨げ、有糸分裂の変化と細胞死を引き起こす抗がん剤です。パクリタキセル (タキソール) は、成長速度の遅い小さな常緑針葉樹であるイチイの木から最初に単離されました。パクリタキセルは当初不足していたため、ヨーロッパイチイの葉から抽出したパクリタキセルの半合成類似体であるドセタキセル (タキソテール) が開発されました。ドセタキセルはパクリタキセルと化学的に 2 か所異なり、より水溶性になっています。カバジタキセルも天然タキソイドの半合成類似体であり、ドセタキセル耐性の一般的な媒介物である P 糖タンパク質に対する親和性がないことを利用して開発されました。

さらに、慢性疾患の罹患率の上昇、がんの罹患率の急増、医療インフラへの投資の増加により、タキサン薬の使用が増加しています。タキサン市場の需要が増加するこれらの要因により、主要な市場プレーヤーは、製品の発売、買収、戦略、契約を通じて、より新しい技術と戦略を実装するよう促されています。

タキサン市場の動向                              

ドライバー

• がんの発症率の上昇

がんは米国および世界中で社会に大きな影響を与えています。がんの統計は、大勢の人々に何が起きているかを示し、がんが社会に及ぼす負担を時系列で示します。がん治療に使用される抗有糸分裂剤タキソールは、細胞分裂を停止してがん細胞の増殖を阻止し、細胞死をもたらします。

国立がん研究所 (NCI) によると、資金援助を受けた臨床試験で、進行性卵巣がん患者の 30 % がタキサン治療に良好な反応を示したことがわかった。臨床診療では、タキサンは現在、転移性乳がんの標準治療となっている。今日、タキソールは世界保健機関の必須医薬品モデル リストに掲載されており、がん細胞を殺す細胞毒性薬である。タキソールは、乳がん、卵巣がん、非小細胞肺がん、膵臓がん、およびエイズ関連のカポジ肉腫の治療に用いられる。

• 政府による資金援助と研究開発への投資

オピオイド使用とアルコール障害の治療における薬物療法の有効性は確立されているものの、専門治療プログラムによるタキサンの実施には限界があることが観察されています。資金、組織構造、労働力のリソースの特定のソースに一定の注意を払い、支払いを将来の潜在的な受益者に合わせる長期的な投資を行う必要があります。医薬品開発の持続可能性、生産性、患者への影響に関する問題は、これまでも、そしてこれからも、単なる業界の産物ではありません。

The funding by the government would result in the patient's safety, cost-savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence the advancements in research and development activities and funding by the government are expected to drive the market growth.

Restraint

• Side effects of drugs incurred with the taxane drugs

Taxanes belong to a class of diterpenes. Taxane drugs (paclitaxel and docetaxel) are used as chemotherapeutic agents. Due to ongoing clinical trials, research studies, type of cancer, type of treatment plan, and drug dosage, the present high cost is expected to show a descending trend in the future. Taxane drugs are most effective for treating breast and prostate cancer. However, certain side effects have been reported. The adverse complications or side effects reported would lead to a decline in sales of the taxane drugs, which would limit the sales of the drugs. In addition, it would affect the reliability of manufacturers involved in this market and hence be expected to restrain the market growth.

Opportunity

• Strategic initiative by market players

The demand for taxane market has increased in the U.S. and Europe owing to the timely treatment of alcohol and opioid disorders. These favorable factors enhance the need for taxane, and to achieve the market demand, minor and major market players are utilizing various strategies.

The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.

These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity to help in future growth and drive market growth.

Challenge

• The lack of skilled professionals required for taxane drug treatment

The lack or shortage of skilled expertise would challenge the pace of recovery and growth in one place. Often the unemployed people in one place have skills that are in short supply elsewhere. Moreover, rapid technological advancement in this field also leads to a lack of expertise.

Physician supply is a term used to describe the number of trained physicians working in a healthcare system or labor market. It is dependent on the number of graduates and the retention rates of the profession. The physician shortage is a growing concern in many countries around the world.

The World Health Organization (WHO) estimated a global shortage of 4.3 million physicians, nurses, and other health professionals. Despite the strong evidence for the effectiveness of drugs in reducing morbidity and mortality, increasing treatment retention, and improving well-being for individuals with taxane, numerous barriers prevent broader access to taxane drug-based treatment.

Moreover, technological advancement is another aspect that leads to the increased demand for skilled professionals. Neurologists report significant unmet supportive care needs and barriers in their centers, with only a small minority rating themselves as competently providing supportive care. There is an urgent need for the education of professionals for the treatment of dementia and procuring available supportive care resources. Lack of trained and experienced professionals and persistent skill gaps limit the employability prospects and access to quality jobs. Therefore, it is apparent that the availability of professionals with adequate skills is challenging the market growth.

Post COVID-19 Impact on Taxane Market

COVID-19 has resulted in a substantial increase in demand for medical supplies from healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to have a big impact on the taxane market.

Recent Developments

• In November 2022, Viatris Inc. and Biocon Biologics Ltd. announced the U.S. launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Both biosimilar products are available in vial and prefilled pen presentations and are interchangeable for the reference brand, LANTUS (insulin glargine), allowing for substitution at the pharmacy counter. Viatris is committed to improving patient access to sustainable, quality and more affordable healthcare. This has helped the company to grow their product portfolio.
• In May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the U.S. launch of its generic pirfenidone, the first AB-rated (fully substitutable) equivalent to Genentech’s Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This prescription oral medicine is immediately available to patients via specialty pharmacies, with a $0 co-pay program for eligible patients. Sandoz is putting patients first by expanding access to generic pirfenidone for those with this rare disease, who will benefit from a more affordable, yet equally effective treatment. This has helped the company to grow its market position and business.

Taxane Scope and Market Size

Taxane market is segmented based on type, drug type, formulation, age group, application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the Difference in your target markets.

By Type

• Paclitaxel
• Docetaxel
• Cabazitaxel

On the basis of type, the North America taxane market is segmented into paclitaxel, docetaxel and cabazitaxel.

By Application

• Ovarian Cancer
• Breast Cancer
• Prostate Cancer
• Non-small Cell Lung Cancer
• Other

On the basis of application, the North America taxane market is segmented into ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer and others.

By Drug Type

• Generics
• Branded

On the basis of drug type, the North America taxane market is segmented into branded and generics.

By Formulation

• Liposomes
• Nanoparticles
• Polymeric Micelles
• Others

On the basis of formulation, the North America taxane market is segmented into liposomes, nanoparticles, polymeric micelles and others.

By Age Group

• Adult
• Geriatric

On the basis of age group, the North America taxane market is segmented into adults and geriatric.

By End User

• Hospitals
• Ambulatory surgical centers
• Specialty clinics
• Others

On the basis of end user, the North America taxane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others.

By Distribution Channel

• Direct tender
• Retail Sales

On the basis of distribution channel, the North America taxane market is segmented into direct tender, retail sales.

North America Taxane Market Regional Analysis

The taxane market is analyzed and market size information is provided by type, drug type, formulation, age group, application, end user and distribution channel.

The countries covered in the taxane market report are U.S., Canada, Mexico.

In 2022, U.S. is dominating due to the presence of key market players along the largest consumer market with high GDP. U.S is expected to grow due to rise in technological advancement in drug treatments.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Taxane market also provides you with detailed market analysis for every country growth in healthcare industry. Moreover, it provides detailed information regarding healthcare services and treatments, impact of regulatory scenarios, and trending parameters regarding Taxane Market.

Competitive Landscape and Taxane Market Share Analysis

タキサン市場の競争状況は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、技術ライフライン曲線が含まれます。提供されている上記のデータ ポイントは、タキサン薬に関連する会社の焦点にのみ関連しています。

タキサン市場を扱っている主要企業としては、Viatris Inc.、Sandoz International GmbH (A Novartis Division)、sanofi-aventis US LLC、Hikma Pharmaceuticals PLC、Pfizer Inc.、Dr. Reddy's Laboratories Ltd.、Taxane Healthcare、Bristol-Myers Squibb Company、Fresenius Kabi AG (Fresenius SE & Co. KGaA の子会社)、SAMYANG HOLDINGS CORPORATION.、Luye Pharma Group、Elevar Therapeutics、Huiang Pharmaceutical Co Ltd.、Shenzhen Main Luck Phar maceuticals Inc.、Accord Healthcare、Torrent Pharmaceuticals Ltd.、Panacea Biotec、RPG Life Sciences Limited.、Aureate Healthcare、Samarth Life Sciences Pvt. Ltd.、Cipla Inc.、Hetero Healthcare Limited.、AqVida GmbH、Ingenus Pharmaceuticals, LLC などがあります。

主要な市場プレーヤーによる合併、買収、合意などの戦略的提携により、タキサン系医薬品の成長がさらに加速すると期待されています。

市場プレーヤーによるコラボレーション、製品の発売、事業拡大、賞や表彰、合弁事業、その他の戦略は、タキサン市場における企業の足跡を強化し、組織の利益成長にも利益をもたらします。

研究方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、北米と地域、ベンダー シェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。

SKU-68750